Cargando…

Xanthine Oxidoreductase Inhibitor Use Associated With Reduced Risk of Sarcopenia and Severe Sarcopenia in Patients Undergoing Hemodialysis

BACKGROUND: Xanthine oxidoreductase (XOR) inhibition reduces reactive oxygen species (ROS) production and enhances adenosine triphosphate (ATP) synthesis. We investigated the protective effects of XOR inhibitor treatment on sarcopenia, frequently observed in patients undergoing hemodialysis (HD), in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurajoh, Masafumi, Mori, Katsuhito, Miyabe, Mizuki, Matsufuji, Shota, Kizu, Akane, Tsujimoto, Yoshihiro, Emoto, Masanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859856/
https://www.ncbi.nlm.nih.gov/pubmed/35198574
http://dx.doi.org/10.3389/fmed.2022.817578
_version_ 1784654547194478592
author Kurajoh, Masafumi
Mori, Katsuhito
Miyabe, Mizuki
Matsufuji, Shota
Kizu, Akane
Tsujimoto, Yoshihiro
Emoto, Masanori
author_facet Kurajoh, Masafumi
Mori, Katsuhito
Miyabe, Mizuki
Matsufuji, Shota
Kizu, Akane
Tsujimoto, Yoshihiro
Emoto, Masanori
author_sort Kurajoh, Masafumi
collection PubMed
description BACKGROUND: Xanthine oxidoreductase (XOR) inhibition reduces reactive oxygen species (ROS) production and enhances adenosine triphosphate (ATP) synthesis. We investigated the protective effects of XOR inhibitor treatment on sarcopenia, frequently observed in patients undergoing hemodialysis (HD), in which increased ROS and ATP shortage are known to be involved. METHODS: This retrospective cross-sectional study included 296 HD patient (203 males, 93 females). Muscle mass, physical performance, and muscle strength were assessed using dual-energy X-ray absorptiometry, five-time chair stand testing, and handgrip strength, respectively. The Asian Working Group for Sarcopenia 2019 criteria were used to define low muscle mass, low physical performance, and low muscle strength, as well as sarcopenia and severe sarcopenia. RESULTS: Sarcopenia and severe sarcopenia prevalence rates were 42.2 and 20.9%, respectively. XOR inhibitor users (n = 119) showed a significantly (p < 0.05) lower prevalence of sarcopenia and severe sarcopenia, as well as reduced muscle mass, physical performance, and muscle strength than non-users (n = 177). Multivariate logistic regression analyses also revealed XOR inhibitor use to be significantly associated with low muscle mass [odds ratio (OR), 0.384; 95% confidence interval (CI), 0.183–0.806; p = 0.011] and low physical performance (OR, 0.286; 95% CI, 0.142–0.578; p < 0.001), while significance with low muscle strength was borderline. Furthermore, XOR inhibitor use was significantly associated with sarcopenia (OR, 0.462; 95% CI, 0.226–0.947; p = 0.035) and severe sarcopenia (OR, 0.236; 95% CI, 0.091–0.614; p = 0.003). CONCLUSIONS: XOR inhibitor use was significantly associated with reduced risk of sarcopenia/severe sarcopenia in HD patients, suggesting that XOR inhibitor treatment has protective effects on sarcopenia in HD patients.
format Online
Article
Text
id pubmed-8859856
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88598562022-02-22 Xanthine Oxidoreductase Inhibitor Use Associated With Reduced Risk of Sarcopenia and Severe Sarcopenia in Patients Undergoing Hemodialysis Kurajoh, Masafumi Mori, Katsuhito Miyabe, Mizuki Matsufuji, Shota Kizu, Akane Tsujimoto, Yoshihiro Emoto, Masanori Front Med (Lausanne) Medicine BACKGROUND: Xanthine oxidoreductase (XOR) inhibition reduces reactive oxygen species (ROS) production and enhances adenosine triphosphate (ATP) synthesis. We investigated the protective effects of XOR inhibitor treatment on sarcopenia, frequently observed in patients undergoing hemodialysis (HD), in which increased ROS and ATP shortage are known to be involved. METHODS: This retrospective cross-sectional study included 296 HD patient (203 males, 93 females). Muscle mass, physical performance, and muscle strength were assessed using dual-energy X-ray absorptiometry, five-time chair stand testing, and handgrip strength, respectively. The Asian Working Group for Sarcopenia 2019 criteria were used to define low muscle mass, low physical performance, and low muscle strength, as well as sarcopenia and severe sarcopenia. RESULTS: Sarcopenia and severe sarcopenia prevalence rates were 42.2 and 20.9%, respectively. XOR inhibitor users (n = 119) showed a significantly (p < 0.05) lower prevalence of sarcopenia and severe sarcopenia, as well as reduced muscle mass, physical performance, and muscle strength than non-users (n = 177). Multivariate logistic regression analyses also revealed XOR inhibitor use to be significantly associated with low muscle mass [odds ratio (OR), 0.384; 95% confidence interval (CI), 0.183–0.806; p = 0.011] and low physical performance (OR, 0.286; 95% CI, 0.142–0.578; p < 0.001), while significance with low muscle strength was borderline. Furthermore, XOR inhibitor use was significantly associated with sarcopenia (OR, 0.462; 95% CI, 0.226–0.947; p = 0.035) and severe sarcopenia (OR, 0.236; 95% CI, 0.091–0.614; p = 0.003). CONCLUSIONS: XOR inhibitor use was significantly associated with reduced risk of sarcopenia/severe sarcopenia in HD patients, suggesting that XOR inhibitor treatment has protective effects on sarcopenia in HD patients. Frontiers Media S.A. 2022-02-07 /pmc/articles/PMC8859856/ /pubmed/35198574 http://dx.doi.org/10.3389/fmed.2022.817578 Text en Copyright © 2022 Kurajoh, Mori, Miyabe, Matsufuji, Kizu, Tsujimoto and Emoto. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Kurajoh, Masafumi
Mori, Katsuhito
Miyabe, Mizuki
Matsufuji, Shota
Kizu, Akane
Tsujimoto, Yoshihiro
Emoto, Masanori
Xanthine Oxidoreductase Inhibitor Use Associated With Reduced Risk of Sarcopenia and Severe Sarcopenia in Patients Undergoing Hemodialysis
title Xanthine Oxidoreductase Inhibitor Use Associated With Reduced Risk of Sarcopenia and Severe Sarcopenia in Patients Undergoing Hemodialysis
title_full Xanthine Oxidoreductase Inhibitor Use Associated With Reduced Risk of Sarcopenia and Severe Sarcopenia in Patients Undergoing Hemodialysis
title_fullStr Xanthine Oxidoreductase Inhibitor Use Associated With Reduced Risk of Sarcopenia and Severe Sarcopenia in Patients Undergoing Hemodialysis
title_full_unstemmed Xanthine Oxidoreductase Inhibitor Use Associated With Reduced Risk of Sarcopenia and Severe Sarcopenia in Patients Undergoing Hemodialysis
title_short Xanthine Oxidoreductase Inhibitor Use Associated With Reduced Risk of Sarcopenia and Severe Sarcopenia in Patients Undergoing Hemodialysis
title_sort xanthine oxidoreductase inhibitor use associated with reduced risk of sarcopenia and severe sarcopenia in patients undergoing hemodialysis
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859856/
https://www.ncbi.nlm.nih.gov/pubmed/35198574
http://dx.doi.org/10.3389/fmed.2022.817578
work_keys_str_mv AT kurajohmasafumi xanthineoxidoreductaseinhibitoruseassociatedwithreducedriskofsarcopeniaandseveresarcopeniainpatientsundergoinghemodialysis
AT morikatsuhito xanthineoxidoreductaseinhibitoruseassociatedwithreducedriskofsarcopeniaandseveresarcopeniainpatientsundergoinghemodialysis
AT miyabemizuki xanthineoxidoreductaseinhibitoruseassociatedwithreducedriskofsarcopeniaandseveresarcopeniainpatientsundergoinghemodialysis
AT matsufujishota xanthineoxidoreductaseinhibitoruseassociatedwithreducedriskofsarcopeniaandseveresarcopeniainpatientsundergoinghemodialysis
AT kizuakane xanthineoxidoreductaseinhibitoruseassociatedwithreducedriskofsarcopeniaandseveresarcopeniainpatientsundergoinghemodialysis
AT tsujimotoyoshihiro xanthineoxidoreductaseinhibitoruseassociatedwithreducedriskofsarcopeniaandseveresarcopeniainpatientsundergoinghemodialysis
AT emotomasanori xanthineoxidoreductaseinhibitoruseassociatedwithreducedriskofsarcopeniaandseveresarcopeniainpatientsundergoinghemodialysis